回溯:一个通过家庭外展提高BRCA1和BRCA2突变携带者识别与遗传咨询的拟议框架
2016年5月美国国家癌症研究所召开研讨会提出Traceback概念框架,旨在识别并基因检测既往诊断但未转诊的卵巢癌患者及其他未被识别的BRCA1/BRCA2突变携带者,以发现高危家庭并减少健康差异。本报告汇总多学科专家讨论,为试点研究提供框架以评估可行性和伦理后勤考量。
要点
- Traceback框架针对既往诊断但未转诊的卵巢癌等患者进行BRCA1/BRCA2检测。
- 该框架有望覆盖历史上未寻求或未获得遗传咨询的种族、民族和社会经济群体。
- 报告为试点研究提供框架以评估可行性和伦理后勤考量。
核心结论
- Traceback项目可为识别未转诊的BRCA1/BRCA2突变携带者及其家庭提供重要机会,并有助于减少种系BRCA突变女性的健康差异。
研究设计与样本
- 2016年5月美国国家癌症研究所癌症预防部和癌症控制与人口科学部召开研讨会,汇集遗传学、肿瘤学、心理学、流行病学、基因组学、成本效果建模、病理学、生物伦理学和患者倡导领域的国际专家讨论Traceback概念框架。
主要发现
- BRCA1和BRCA2突变在卵巢癌女性中常见,但许多此类女性未接受检测,尤其当诊断早于检测指南变化时。
- 未能识别先证者中的突变携带者意味着错失通过风险降低干预预防突变携带者亲属患癌及为非携带者提供适当 reassurance 的机会。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer. The concept, designated Traceback, was prompted by the recognition that although BRCA1 and BRCA2 mutations are frequent in women with ovarian cancer, many such women have not been tested, especially if their diagnosis predated changes in testing guidelines. The failure to identify mutation carriers among probands represents a lost opportunity to prevent cancer in unsuspecting relatives through risk-reduction intervention in mutation carriers and to provide appropriate reassurances to noncarriers. The Traceback program could provide an important opportunity to reach families from racial, ethnic, and socioeconomic groups who historically have not sought or been offered genetic counseling and testing and thereby contribute to a reduction in health disparities in women with germline BRCA mutations. To achieve an interdisciplinary perspective, the workshop assembled international experts in genetics, medical and gynecologic oncology, clinical psychology, epidemiology, genomics, cost-effectiveness modeling, pathology, bioethics, and patient advocacy to identify factors to consider when undertaking a Traceback program. This report highlights the workshop deliberations with the goal of stimulating research and providing a framework for pilot studies to assess the feasibility and ethical and logistical considerations related to the development of best practices for implementation of Traceback studies.
引用
- Samimi G, Bernardini MQ, Brody LC, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. J Clin Oncol. 2017. PMID: 28398847. doi:10.1200/JCO.2016.70.3439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。